B Vitamins, Beta-Glucans, and Immune Support

Evidence Review

Trained Immunity and Beta-Glucan Signaling

Vuscan et al. (2024) provided some of the most mechanistically detailed evidence to date that S. cerevisiae beta-glucans induce trained immunity — a form of innate immune memory [1]. In this study, human monocytes exposed to yeast beta-glucans showed durable epigenetic reprogramming via H3K4me3 (trimethylation of histone H3 lysine 4) at promoters of pro-inflammatory genes including TNF-α and IL-6. These changes persisted long after the initial exposure and primed cells to respond more vigorously to subsequent bacterial or fungal challenges — without constitutively elevating inflammation.

This is mechanistically distinct from immunostimulants that simply raise cytokine levels. Trained immunity involves metabolic reprogramming of immune cells toward oxidative phosphorylation and glycolysis, producing a more capable and durable response [1]. The study used both in vitro human monocyte models and in vivo murine models, with concordant findings.

Nutraceutical Beta-Glucan Review

Ciecierska et al. (2019) conducted a comprehensive review of beta-glucan functions across food sources including oat, barley, and yeast [2]. Key findings include:

• Yeast beta-1,3/1,6-glucan has higher biological activity than cereal beta-1,3-glucan due to the additional branching at the 1,6 position, which enhances binding to immune receptors
• Cholesterol-lowering effects were documented at doses as low as 3 grams per day
• Beta-glucans modulate the gut microbiome by selectively feeding Lactobacillus and Bifidobacterium species
• No significant adverse effects were reported at supplemental doses up to 15 grams per day in reviewed trials

Metabolic and Microbiome Effects

Mitchelson et al. (2022) investigated yeast beta-glucan in a sophisticated model designed to assess gut microbiota-dependent effects [3]. Mice were colonized with gut microbiota from obese human donors with type 2 diabetes — creating a model closer to the human metabolic disease state than conventional rodent studies. Yeast beta-glucan supplementation over 12 weeks produced:

• Significant improvements in fasting insulin and HOMA-IR (homeostatic model assessment of insulin resistance)
• Reduced hepatic triglyceride accumulation
• Shifts in microbiome composition, including increased Akkermansia muciniphila and decreased pro-inflammatory Proteobacteria
• Lower circulating LPS-binding protein, suggesting reduced intestinal barrier leakage

The gut microbiome changes appeared to mediate much of the metabolic benefit, indicating nutritional yeast's beta-glucans act as a prebiotic fiber in addition to their direct immune effects.

Protein and Bioactive Compound Profile

Jach and Malm (2022) reviewed yeast species including S. cerevisiae as sources of nutritional compounds for humans, finding that yeast provides complete amino acid profiles, essential fatty acids, minerals (zinc, selenium, chromium, iron), and bioactive compounds including coenzyme Q10 and ergothioneine [4]. The selenium content is of particular interest — S. cerevisiae accumulates selenium efficiently, and selenium-enriched nutritional yeast is sometimes used as a bioavailable selenium supplement. The paper notes that yeast cell wall polysaccharides (primarily beta-glucan and mannan) account for most of the immunomodulatory activity.

Cholesterol Evidence from Clinical Review

Bell et al. (1999) reviewed human and animal evidence for beta-glucan from both oats and yeast on serum lipids, finding consistent LDL reductions across multiple study designs [5]. Yeast beta-glucan at 3–6 g/day produced LDL reductions of 6–10% in human trials. The mechanism operates via bile acid sequestration: viscous beta-glucan binds bile acids in the ileum, reducing their enterohepatic recycling and forcing the liver to synthesize new bile acids from LDL cholesterol, thereby depleting circulating LDL. The 1999 review predates more recent mechanistic work but provides the clinical quantification that subsequent studies have extended.

Evidence Limitations

Most beta-glucan immunology research used isolated extracts at doses higher than typical dietary nutritional yeast consumption. Direct RCTs on whole nutritional yeast (as opposed to purified beta-glucan supplements) are limited. The metabolic and cholesterol effects are well-supported by both mechanistic and clinical data; the trained immunity findings, while mechanistically compelling, require larger human clinical trials to quantify the clinical magnitude. People with autoimmune conditions should consult a clinician before significantly increasing beta-glucan intake, as immune priming could theoretically be counterproductive in those settings.